Aptitude Receives Funding to Develop Tests for Sexually Transmitted Infections

Aptitude Medical Systems has been awarded a significant grant from the Bill & Melinda Gates Foundation to develop point-of-care diagnostic tests for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV). This funding is pivotal for tackling the global public health challenges posed by sexually transmitted infections (STIs), particularly in low- to middle-income countries.

The Metrix platform from Aptitude, one of only four platforms to have received an Emergency Use Authorization (EUA) for an over-the-counter COVID-19 molecular test, showcases the platform's potential for user-friendly, effective diagnostic solutions, irrespective of an individual's training level.

"We aim to empower individuals to take control of their health with prompt, reliable, inexpensive diagnostic tools," said Kevin Nichols, VP of Strategic Initiatives at Aptitude. "Imagine the capability to directly detect and reflex to the right treatment for most pervasive and threatening STIs - directly in a doctor's office, clinic, pharmacy or at home. The development of these point-of-care tests for STIs represents a significant step in democratizing diagnostics, making healthcare more equitable across all socio-economic levels."